^
Association details:
| Biomarker: | BRCA wild-type + TP53 mutation |
|---|---|
| Cancer: | Breast Cancer |
| Drug: | Talzenna (talazoparib) (PARP inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
6186 / 15 - Patient-derived tumor organoids with p53 mutations, and not wild-type p53, demonstrate synergistic sensitivity to treatment with temozolomide in combination with talazoparib PARP inhibitor
Published date:
03/15/2023
Excerpt:
Here, we evaluated the sensitivity of wild-type BRCA1/2 breast and lung PDTO with either mtp53 or wild-type p53 (wtp53) to the combination of DNA damaging agent temozolomide plus the PARPi talazoparib….Three breast cancer and two lung cancer PDTO with mtp53 presented synergistic cytotoxicity of the combination treatment.
Secondary therapy:
temozolomide
